By Dominic Chopping

Novo Nordisk A/S (NOV) said Monday it is investing DKK1.5 billion in new haemophilia treatment manufacturing facility in Denmark.

The Danish pharmaceutical company said the new facility in Kalundborg, Denmark will produce active pharmaceutical ingredients for its NovoSeven product as well as future products for treating haemophilia.

The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people, it said.

The facility is expected to be approved and fully operational in 2020.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novo Nordisk Charts.